Claims for Patent: 10,155,810

Summary for Patent: 10,155,810

Title:	Provasopressin antagonists and uses thereof
Abstract:	Provided herein are pro-VP antagonists, such as antibodies and antigen-binding portions thereof specific for pro-VP, for identifying and targeting expressing cancer cells. Applicants additionally provide methods of using said compositions, for example to image cancer cells in vivo and in biological samples. The compositions may also be used for treating patients suffering from a provasopressin-expressing cancer. Provasopressin-expressing cancers include neuroendocrine cancer, pancreatic cancer, and prostate cancer.
Inventor(s):	North; William G. (Hanover, NH), Pang; Roy H. L. (Etna, NH)
Assignee:	Woomera Therapeutics (Lebanon, NH)
Application Number:	15/289,260
Patent Claims:	1. A method of treating a provasopressin-expres sing (pro-VP-expressing) cancer, comprising administering, to a patient in need thereof, a therapeutically effective amount of a provasopressin-binding antibody or an antigen-binding portion thereof specific for the C-terminal 18-amino-acid VAG region of provasopressin (pro-VP), wherein the provasopressin-binding antibody is MAG-1, a humanized antibody thereof, or a chimeric antibody thereof, and wherein the cancer is a neuroendocrine cancer or a pancreatic cancer. 2. The method of claim 1, wherein the neuroendocrine cancer is a brain, gastroenteric, ovarian, endomedrial, testicular, adrenal, or skin cancer. 3. The method of claim 1, wherein the antigen-binding portion thereof is scFv, Fab, F(ab').sub.2, Fd, Fv, or dAb. 4. The method of claim 1, further comprising administering an effective amount of a pharmaceutical composition comprising a chemotherapeutic agent. 5. The method of claim 4, wherein the pharmaceutical composition comprising a chemotherapeutic agent further comprises epinephrine. 6. The method of claim 4, wherein the pharmaceutical compositions are administered in a single formulation. 7. The method of claim 1, further comprising administering an effective amount of a pharmaceutical composition comprising at least one of dexamethasone, IBMX, 8-bromoadenosine 3',5'-cyclic monophosphate (8br-cAMP), cyclophosphamide, cisplatin, etoposide VP-16, and forskolin. 8. The method of claim 1, further comprising performing surgical removal of at least one tumor from the patient. 9. The method of claim 1, further comprising performing radiation therapy. 10. The method of claim 1, further comprising administering a somatostatin or an analogue thereof. 11. The method of claim 1, further comprising administering at least one of imatinib, sunitinib, temozolide, thalidomide, sorafenib, and panitumumab. 12. The method of claim 1, wherein the antibody or antibody-binding portion thereof comprises a label. 13. The method of claim 12, wherein the label is selected from the group consisting of a fluorescent label, a radiolabel, a toxin, a metal compound, and biotin. 14. The method of claim 13, wherein the fluorescent label is selected from the group consisting of Texas Red, phycoerythrin (PE), cytochrome c, and fluorescent isothiocyanate (FITC). 15. The method of claim 13, wherein the radiolabel is selected from the group of .sup.32P, .sup.33P, .sup.43K, .sup.47Sc, .sup.52Fe, .sup.57Co, .sup.64Cu, .sup.67Ga, .sup.67Cu, .sup.68Ga, .sup.71Ge, .sup.75Br, .sup.76Br, .sup.77Br, .sup.77As, .sup.77Br, .sup.81Rb/.sup.81MKr, .sup.87MSr, .sup.90Y, .sup.97Ru, .sup.99Tc, .sup.100Pd, .sup.101Rh, .sup.103Pb, .sup.105Rh, .sup.109Pd, .sup.111Ag, .sup.111In, .sup.113In, .sup.119Sb, .sup.121Sn, .sup.123I, .sup.125I, .sup.127Cs, .sup.128Ba, .sup.129Cs, .sup.131I, .sup.131Cs, .sup.143Pr, .sup.153Sm, .sup.161Tb, .sup.166Ho, .sup.169Eu, .sup.177Lu, .sup.186Re, .sup.188Re, .sup.189Re, .sup.191Os, .sup.193Pt, .sup.194Ir, .sup.197Hg, .sup.199Au, .sup.203Pb, .sup.211At, .sup.212Bi and .sup.213Bi. 16. The method of claim 13, wherein the toxin is selected from the group consisting of ricin, ricin A chain (ricin toxin), Pseudomonas exotoxin (PE), diphtheria toxin (DT), Clostridium perfringens phospholipase C (PLC), bovine pancreatic ribonuclease (BPR), pokeweed antiviral protein (PAP), abrin, abrin A chain (abrin toxin), cobra venom factor (CVF), gelonin (GEL), saporin (SAP), modeccin, viscumin and volkensin. 17. A method of killing or inhibiting the growth of a provasopressin-expressing cancer cell, comprising contacting the provasopressin-expressing cancer cell with a provasopressin-binding antibody or an antigen-binding portion thereof specific for the C-terminal 18-amino-acid VAG region of provasopressin (pro-VP), wherein the provasopressin-binding antibody is MAG-1, a humanized antibody thereof, or a chimeric antibody thereof, and wherein the provasopressin-expressing cancer cell is from a neuroendocrine cancer or a pancreatic cancer. 18. The method of claim 17, further comprising contacting the provasopres sin-expressing cancer cell with a chemotherapeutic agent.

Details for Patent 10,155,810

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147	09/27/2006		2031-11-11